|
1
|
Burstein HJ: Novel agents and future
directions for refractory breast cancer. Semin Oncol. 38(Suppl 2):
S17–S24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Higgins MJ and Stearns V: Pharmacogenetics
of endocrine therapy for breast cancer. Annu Rev Med. 62:281–293.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Al Saleh S, Sharaf LH and Luqmani YA:
Signalling pathways involved in endocrine resistance in breast
cancer and associations with epithelial to mesenchymal transition.
Int J Oncol. 38:1197–1217. 2011.PubMed/NCBI
|
|
4
|
Goldhirsch A, Wood WC, Gelber RD, Coates
AS, Thürlimann B and Senn HJ; 10th St. Gallen conference. Progress
and promise: highlights of the international expert consensus on
the primary therapy of early breast cancer 2007. Ann Oncol.
18:1133–1144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Laubach J, Richardson P and Anderson K:
Multiple myeloma. Annu Rev Med. 62:249–264. 2011. View Article : Google Scholar
|
|
6
|
Obeng EA, Carlson LM, Gutman DM,
Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce
a terminal unfolded protein response in multiple myeloma cells.
Blood. 107:4907–4916. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meister S, Schubert U, Neubert K, Herrmann
K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann
M, Jäck HM and Voll RE: Extensive immunoglobulin production
sensitizes myeloma cells for proteasome inhibition. Cancer Res.
67:1783–1792. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fels DR, Ye J, Segan AT, Kridel SJ,
Spiotto M, Olson M, Koong AC and Koumenis C: Preferential
cytotoxicity of bortezomib toward hypoxic tumor cells via
overactivation of endoplasmic reticulum stress pathways. Cancer
Res. 68:9323–9330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kawaguchi T, Miyazawa K, Moriya S, Ohtomo
T, Che XF, Naito M, Itoh M and Tomoda A: Combined treatment with
bortezomib plus bafilomycin A1 enhances the cytocidal effect and
induces endoplasmic reticulum stress in U266 myeloma cells:
crosstalk among proteasome, autophagy-lysosome and ER stress. Int J
Oncol. 38:643–654. 2011.
|
|
10
|
Ri M, Iida S, Nakashima T, Miyazaki H,
Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Shiotsu
Y and Ueda R: Bortezomib-resistant myeloma cell lines: a role for
mutated PSMB5 in preventing the accumulation of unfolded proteins
and fatal ER stress. Leukemia. 24:1506–1512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ron D and Walter P: Signal integration in
the endoplasmic reticulum unfolded protein response. Nat Rev Mol
Cell Biol. 8:519–529. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herr I and Debatin K-M: Cellular stress
response and apoptosis in cancer therapy. Blood. 98:2603–2613.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Verfaillie T, Salazar M, Velasco G and
Agostinis P: Linking ER stress to autophagy: potential implications
for cancer therapy. Int J Cell Biol. 2010:1–19. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cardoso F, Durbecq V, Laes JF, Badran B,
Lagneaux L, Bex F, Desmedt C, Willard-Gallo K, Ross JS, Burny A,
Piccart M and Sotiriou C: Bortezomib (PS-341, Velcade) increases
the efficacy of trastuzumab (Herceptin) in HER-2-positive breast
cancer cells in a synergistic manner. Mol Cancer Ther. 5:3042–3051.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Milani M, Rzymski T, Mellor HR, Pike L,
Bottini A, Generali D and Harris AL: The role of ATF4 stabilization
and autophagy in resistance of breast cancer cells treated with
Bortezomib. Cancer Res. 69:4415–4423. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Periyasamy-Thandavan S, Jackson WH,
Samaddar JS, Erickson B, Barrett JR, Raney L, Gopal E, Ganapathy V,
Hill WD, Bhalla KN and Schoenlein PV: Bortezomib blocks the
catabolic process of autophagy via a cathepsin-dependent mechanism,
affects endoplasmic reticulum stress and induces caspase-dependent
cell death in antiestrogen-sensitive and resistant ER+
breast cancer cells. Autophagy. 6:19–35. 2010. View Article : Google Scholar
|
|
17
|
Engel RH, Brown JA, Von Roenn JH, O’Regan
RM, Bergan R, Badve S, Rademaker A and Gradishar WJ: A phase II
study of single agent bortezomib in patients with metastatic breast
cancer: a single institution experience. Cancer Invest. 25:733–737.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ishii Y, Papa L, Bahadur U, Yue Z,
Aguirre-Ghiso J, Shioda T, Waxman S and Germain D: Bortezomib
enhances the efficacy of fulvestrant by amplifying the aggregation
of the estrogen receptor, which leads to a proapoptotic unfolded
protein response. Clin Cancer Res. 17:2292–2300. 2011. View Article : Google Scholar
|
|
19
|
Jones MD, Liu JC, Barthel TK, Hussain S,
Lovria E, Cheng D, Schoonmaker JA, Mulay S, Ayers DC, Bouxsein ML,
Stein GS, Mukherjee S and Lian JB: A proteasome inhibitor,
bortezomib, inhibits breast cancer growth and reduces osteolysis by
down-regulating metastatic genes. Clin Cancer Res. 16:4978–4989.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mizushima N and Levine B: Autophagy in
mammalian development and differentiation. Nat Cell Biol.
12:823–830. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Janku F, McConkey DJ, Hong DS and Kurzrock
R: Autophagy as a target for anticancer therapy. Nat Rev Clin
Oncol. 8:528–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Korolchuk VI, Menzies FM and Rubinsztein
DC: Mechanisms of cross-talk between the ubiquitin-proteasome and
autophagy-lysosome systems. FEBS Lett. 584:1393–1398. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kirkin V, McEwan DG, Novak I and Dikic I:
A role for ubiquitin in selective autophagy. Mol Cell. 34:259–269.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mizushima N and Yoshimori T: How to
interpret LC3 immuno-blotting. Autophagy. 3:542–545. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamamoto A, Tagawa Y, Yoshimori T,
Moriyama Y, Masaki R and Tashiro Y: Bafilomycin A1 prevents
maturation of autophagic vacuoles by inhibiting fusion between
autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E
cells. Cell Struct Funct. 123:33–42. 1998. View Article : Google Scholar
|
|
26
|
Nakamura M, Kikukawa Y, Takeya M, Mitsuya
H and Hata H: Clarithromycin attenuates autophagy in myeloma cells.
Int J Oncol. 37:815–820. 2010.PubMed/NCBI
|
|
27
|
Gay F, Rajkumar SV, Coleman M, Kumar S,
Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ,
Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R,
Kyle RA, Greipp PR, Stewart AK and Niesvizky R: Clarithromycin
(Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus
lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed
myeloma. Am J Hematol. 85:664–669. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Niesvizky R, Jayabalan DS, Christos PJ,
Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle
K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J,
Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S and
Coleman M: BiRD (Biaxin [clarithromycin]/Revlimid
[lenalidomide]/dexamethasone) combination therapy results in high
complete- and overall-response rates in treatment-naive symptomatic
multiple myeloma. Blood. 111:1101–1109. 2008.
|
|
29
|
Govi S, Dognini GP, Licata G, Crocchiolo
R, Resti AG, Ponzoni M and Ferreri AJ: Six-month oral
clarithromycin regimen is safe and active in extranodal marginal
zone B-cell lymphomas: final results of a single-centre phase II
trial. Br J Haematol. 50:226–229. 2010.PubMed/NCBI
|
|
30
|
Ohe M and Hashino S: Successful treatment
with clarithromycin for mixed phenotype acute leukemia, T/myeloid,
NOS (in Japanese). Rinsho Ketsueki. 51:297–299. 2010.PubMed/NCBI
|
|
31
|
Mikasa K, Sawaki M, Kita E, Hamada K,
Teramoto S, Sakamoto M, Maeda K, Konishi M and Narita N:
Significant survival benefit to patients with advanced
non-small-cell lung cancer from treatment with clarithromycin.
Chemotherapy. 43:288–296. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wada T, Sata M, Sato J, Tokairin Y,
Machiya J, Hirama N, Arao T, Inoue S, Takabatake N, Shibata Y and
Kubota I: Clarithromycin suppresses invasiveness of human lung
adenocarcinoma cells. Chemotherapy. 53:77–84. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yatsunami J, Fukuno Y, Nagata M, Tsuruta
N, Aoki S, Tominaga M, Kawashima M, Taniguchi S and Hayashi S:
Roxithromycin and clarithromycin, 14-membered ring macrolides,
potentiate the antitumor activity of cytotoxic agents against mouse
B16 melanoma cells. Cancer Lett. 147:17–24. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hamada K, Kita E, Sawaki M, Mikasa K and
Narita N: Antitumor effect of erythromycin in mice. Chemotherapy.
41:59–69. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Malfertheiner P, Megraud F, O’Morain C,
Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N and
Kuipers EJ: Current concepts in the management of Helicobacter
pylori infection: the Maastricht III Consensus Report. Gut.
56:772–781. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ohara T, Morishita T, Suzuki H, Masaoka T,
Ishii H and Hibi T: Antibiotics directly induce apoptosis in B cell
lymphoma cells derived from BALB/c mice. Anticancer Res.
24:3723–3730. 2004.PubMed/NCBI
|
|
37
|
Ohtomo T, Miyazawa K, Naito M, Moriya S,
Kuroda M, Itoh M and Tomoda A: Cytoprotective effect of imatinib
mesylate in non-BCR-ABL-expressing cells along with autophagosome
formation. Biochem Biophys Res Commun. 391:310–315. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moriya S, Miyazawa K, Kawaguchi T, Che XF
and Tomoda A: Involvement of endoplasmic reticulum stress-mediated
CHOP (GADD153) induction in the cytotoxicity of
2-aminophenoxazine-3-one in cancer cells. Int J Oncol. 39:981–988.
2011.PubMed/NCBI
|
|
39
|
Tabas I and Ron D: Integrating the
mechanisms of apoptosis induced by endoplasmic reticulum stress.
Nat Cell Biol. 13:184–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hoang B, Benavides A, Shi Y, Frost P and
Lichtenstein A: Effect of autophagy on multiple myeloma cell
viability. Mol Cancer Ther. 8:1974–1984. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nishida Y, Arakawa S, Fujitani K,
Yamaguchi H, Mizuta T, Kanaseki T, Komatsu M, Otsu K, Tsujimoto Y
and Shimizu S: Discovery of Atg5/Atg7-independent alternative
macroautophagy. Nature. 461:654–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shimizu S, Arakawa S and Nishida Y:
Autophagy takes an alternative pathway. Autophagy. 6:290–291. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Belloni D, Veschini L, Foglieni C,
Dell’Antonio G, Caligaris-Cappio F, Ferrarini M and Ferrero E:
Bortezomib induces autophagic death in proliferating human
endothelial cells. Exp Cell Res. 316:1010–1018. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhu K, Dunner K Jr and McConkey DJ:
Proteasome inhibitors activate autophagy as a cytoprotective
response in human prostate cancer cells. Oncogene. 29:451–462.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rzymski T, Milani M, Singleton DC and
Harris AL: Role of ATF4 in regulation of autophagy and resistance
to drugs and hypoxia. Cell Cycle. 8:3838–3847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rzymski T, Milani M, Pike L, Buffa F,
Mellor HR, Winchester L, Pires I, Hammond E, Ragoussis I and Harris
AL: Regulation of autophagy by ATF4 in response to severe hypoxia.
Oncogene. 29:4424–4435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Salazar M, Carracedo A, Salanueva IJ,
Hernández-Tiedra S, Lorente M, Egia A, Vázquez P, Blázquez C,
Torres S, García S, Nowak J, Fimia GM, Piacentini M, Cecconi F,
Pandolfi PP, González-Feria L, Iovanna JL, Guzmán M, Boya P and
Velasco G: Cannabinoid action induces autophagy-mediated cell death
through stimulation of ER stress in human glioma cells. J Clin
Invest. 119:1359–1372. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hideshima T, Bradner JE, Wong J, Chauhan
D, Richardson P, Schreiber SL and Anderson KC: Small-molecule
inhibition of proteasome and aggresome function induces synergistic
antitumor activity in multiple myeloma. Proc Natl Acad Sci USA.
102:8567–8572. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lee JY, Koga H, Kawaguchi Y, Tang W, Wong
E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, Taylor JP, Cuervo
AM and Yao TP: HDAC6 controls autophagosome maturation essential
for ubiquitin-selective quality-control autophagy. EMBO J.
29:969–980. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Iwamoto T, Ishibashi M, Fujieda A, Masuya
M, Katayama N and Okuda M: Drug interaction between itraconazole
and bortezomib: exacerbation of peripheral neuropathy and
thrombocytopenia induced by bortezomib. Pharmacotherapy.
30:661–665. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Suzuki A, Iida I, Hirota M, Akimoto M,
Higuchi S, Suwa T, Tani M, Ishizaki T and Chiba K: CYP isoforms
involved in the metabolism of clarithromycin in vitro: comparison
between the identification from disappearance rate and that from
formation rate of metabolites. Drug Metab Pharmacokinet.
18:104–113. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jain A, Lamark T, Sjøttem E, Larsen KB,
Awuh JA, Øvervatn A, McMahon M, Hayes JD and Johansen T: p62/SQSTM1
is a target gene for transcription factor NRF2 and creates a
positive feedback loop by inducing antioxidant response
element-driven gene transcription. J Biol Chem. 285:22576–22591.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Thompson HG, Harris JW, Wold BJ, Lin F and
Brody JP: p62 overexpression in breast tumors and regulation by
prostate-derived Ets factor in breast cancer cells. Oncogene.
22:2322–2333. 2003. View Article : Google Scholar : PubMed/NCBI
|
